Icon
+91 94997 68112
Login Register

VIGAMOX (nda021598)- (EQ 0.5% BASE)

MOXIFLOXACIN HYDROCHLORIDE HARROW EYE
EQ 0.5% BASE
Yes No
2020-Mar-29 Expired
None None
None No
VIGAMOX is a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus warneri, Streptococcus pneumoniae, Streptococcus viridans group, Acinetobacter lwoffii, Haemophilus influenzae, Haemophilus parainfluenzae, Chlamydia trachomatis
10 1 9
Total Other Developers 12
Drugs with Suitability No
EQ 0.5% BASE ** ** Up - 6
NDA Sales Available Total Generic Sales Available
Yes 8
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ****** ****** ***. *********** *** ***** ***** **** ****, ******** ****, ******* *** ***, ****** (***) ***
****** ****** ****** ***. *********** *** ****** *****, *******, ******* *** ***, ****** (***) ***
****** ***** *** ***** ******* *********** ****-*, **** **. *-* *** *-*-*, ******* ******** **** ***** **, ****. ****, ******* ****, ****. ****, *********, ****** ******* ******, ***** (***) ***
****** **** ****** *** ***** ********* ******* *** (*** *****) *********** ** ******** *** *** *, ********, *** ****** (**) *****-****, ****** ****** (***) ***
****** ***** ****** ***** ****** ************ ******* *********** ****-***, **** **: *, ** ** **, ***, ** ** **, ****, *****, ***, ************ *******, ********** ******, **********, ********* ******, ***** (***) ***
****** ***** ****** ******** ****** ******* ******* *** *********** ****-**, ****** **. ** & **, ************* ******* ***- *********, ******** ******, **********, ********* ******, ***** (***) ***
****** ***** ***** **** ******* *********** ***-***, ** *****, ****** **** ****, *****, *********** ********** ****, *********, ********* ******, ***** (***) ***
****** ***** ****** *** ***** ****** ******* *********** ****** **. *** - ***, *** & ***, **** ************* ***** *****, *. *. *****, ******** ****, ******** - ************* ******, ******* - ********** ********, *********, ********* ******, ***** (***) ***
****** ******* ***** ****** ******* *********** ****** **. *** - ***, *** & ***, **** ************* ***** *****, *. *. *****, ******** ****, ******** - ************* ******, ******* - ********** ********, *********, ********* ******, ***** (***) ***
****** ******* ******* *************** ******* *********** *********** ******** ***, **** **. ****/****, ******* - *********, ****** - *****, ********, ******* ******, ***** (***) ***
****** ******** ******* *** ******** ************ ******* ******* *********** **/*, ******** ******* *********** *****, *********, ********* ******, ***** (***) ***

Download GenUS Drug Report

Download GenUS Detailed Report

To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.